CINECA IRIS Institutional Research Information System

MINUTOLO, FILIPPO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.184
EU - Europa 8.314
AS - Asia 3.380
AF - Africa 181
SA - Sud America 44
OC - Oceania 28
Continente sconosciuto - Info sul continente non disponibili 3
Totale 27.134
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 14.699
IT - Italia 4.035
CN - Cina 1.371
SE - Svezia 1.136
DE - Germania 797
SG - Singapore 735
BG - Bulgaria 725
TR - Turchia 540
CA - Canada 479
GB - Regno Unito 350
UA - Ucraina 301
VN - Vietnam 286
FI - Finlandia 242
FR - Francia 216
IN - India 202
CH - Svizzera 137
HK - Hong Kong 101
AT - Austria 85
RU - Federazione Russa 80
BE - Belgio 73
NG - Nigeria 67
CI - Costa d'Avorio 64
JP - Giappone 49
SN - Senegal 30
BR - Brasile 27
NL - Olanda 27
KR - Corea 22
AU - Australia 20
IR - Iran 19
ES - Italia 17
PL - Polonia 17
CZ - Repubblica Ceca 14
GR - Grecia 14
MO - Macao, regione amministrativa speciale della Cina 11
DK - Danimarca 10
BJ - Benin 9
IE - Irlanda 9
TW - Taiwan 9
NZ - Nuova Zelanda 8
RO - Romania 8
CL - Cile 6
EC - Ecuador 5
EG - Egitto 5
ID - Indonesia 5
DZ - Algeria 4
MX - Messico 4
RS - Serbia 4
UZ - Uzbekistan 4
CO - Colombia 3
EU - Europa 3
HU - Ungheria 3
IL - Israele 3
LK - Sri Lanka 3
TH - Thailandia 3
AM - Armenia 2
AZ - Azerbaigian 2
JO - Giordania 2
KW - Kuwait 2
LT - Lituania 2
LU - Lussemburgo 2
PK - Pakistan 2
PT - Portogallo 2
SK - Slovacchia (Repubblica Slovacca) 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AR - Argentina 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
DO - Repubblica Dominicana 1
HN - Honduras 1
HR - Croazia 1
KG - Kirghizistan 1
LI - Liechtenstein 1
MY - Malesia 1
NO - Norvegia 1
OM - Oman 1
SA - Arabia Saudita 1
SC - Seychelles 1
SY - Repubblica araba siriana 1
ZA - Sudafrica 1
Totale 27.134
Salva come PNG Salva come JPEG
Città #
Woodbridge 2.088
Ann Arbor 1.419
Fairfield 1.362
Chandler 1.349
Houston 1.230
Serra 1.210
Milan 893
Ashburn 883
Sofia 725
Seattle 546
Wilmington 505
Cambridge 481
Singapore 465
Ottawa 451
Beijing 443
New York 422
Jacksonville 397
Izmir 391
Boardman 343
Princeton 322
Lawrence 275
Nanjing 259
Medford 255
Des Moines 147
Dearborn 146
Rome 145
Dong Ket 136
Bern 122
Istanbul 122
Redwood City 119
Pisa 113
Marseille 111
Boulder 110
Nanchang 109
Florence 108
London 99
Hong Kong 96
San Diego 79
Vienna 75
Lagos 67
Abidjan 64
Jüchen 60
Los Angeles 59
Ogden 56
Brussels 46
Hebei 46
Shanghai 46
Kunming 45
Shenyang 45
Hyderabad 43
Pune 40
Washington 38
Nürnberg 37
Livorno 36
Dallas 35
Norwalk 35
Santa Clara 35
Tianjin 34
Jiaxing 33
Dakar 30
Hefei 29
Auburn Hills 28
Hangzhou 28
Mumbai 28
Guangzhou 27
Changsha 24
Bologna 23
Chicago 23
Frankfurt am Main 23
Fuzhou 23
Jinan 23
Louvain-la-Neuve 21
Vicopisano 20
San Francisco 19
Tokyo 18
Orange 17
Phoenix 16
Pistoia 16
Munich 15
Turin 15
Falls Church 14
Pessac 14
Toronto 14
Talence 13
Brno 12
Caserta 12
Massa 11
Palermo 11
Quanzhou 11
Wuhan 11
Carrara 10
Indiana 10
Piombino 10
Seongbuk-gu 10
Alessandria 9
Altopascio 9
Bathinda 9
Chengdu 9
Cotonou 9
Lucca 9
Totale 20.134
Salva come PNG Salva come JPEG
Nome #
COMPOSTO INIBITORE DELL’ENZIMA LATTATO DEIDROGENASI (LDH) E COMPOSIZIONE FARMACEUTICA CHE COMPRENDE TALE COMPOSTO 272
4-Aryliden-2-methyloxazol-5(4H)-one as a new scaffold for selective reversible MAGL inhibitors 237
GLUT1 and LOX inhibitors as perspective anticancer agents tackling glucose avidity and ECM remodeling in tumors 201
Receptor-based virtual screening evaluation for the identification of estrogen receptor β ligands 185
Synthesis and biological evaluation of non-glucose glycoconjugated N-hydroyxindole class LDH inhibitors as anticancer agents 184
Phenylpropanoids and flavonoids from Phlomis kurdica as inhibitors of human lactate dehydrogenase. 178
Glycoconjugated metal complexes as cancer diagnostic and therapeutic agents 175
Identification of Lactate Dehydrogenase 5 Inhibitors using Pharmacophore- Driven Consensus Docking 169
Nuovi attivatori dell’enzima SIRT1 per il trattamento delle patologie cardiovascolari e cardiometaboliche 167
Salicylaldoxime derivatives as new leads for the development of carbonic anhydrase inhibitors 162
New NO-Releasing Pharmacodynamic Hybrids of Losartan and Its Active Metabolite: Design,Synthesis, and Biopharmacological Properties 162
A Convenient Three-Component Synthesis of Substituted Cyclopentadienyl Tricarbonyl Rhenium Complexes 152
Synthesis of Anthranylaldoxime Derivatives as Estrogen Receptor Ligands and Computational Prediction of Binding Modes 151
Highly Selective Salicylketoxime-Based Estrogen Receptor β Agonists Display Antiproliferative Activities in a Glioma Model 150
First examples of H2S-releasing glycoconjugates: stereoselective synthesis and anticancer activities 149
Phospho-Akt overexpression is prognostic and can be used to tailor the synergistic interaction of Akt inhibitors with gemcitabine in pancreatic cancer 148
Salicylaldoximes and anthranylaldoximes as alternatives to phenol-based estrogen receptor ligands 147
Synthesis and Biological Evaluation of New Glycoconjugated LDH Inhibitors as Anticancer Agents 147
4-[6-(dansylamino)hexylamino]-7-methyl-2-phenyl-1,8-naphthyridine as a new potential fluorescent probe for studying A1-adenosine receptor 144
Anticancer Agents That Counteract Tumor Glycolysis 143
Synthesis and dopaminergic properties of the two enantiomers of 3-(3,4-dimethylphenyl)-1-propylpiperidine, a potent and selective dopamine D4 receptor ligand 143
Salicylaldoximes and anthranylaldoximes as alternatives to phenol-based estrogen receptor ligands 143
Optimization of a Benzoylpiperidine Class Identifies a Highly Potent and Selective Reversible Monoacylglycerol Lipase (MAGL) Inhibitor 143
Risks and Benefits Related to Alimentary Exposure to Xenoestrogens 142
Inhibitors of lactate dehydrogenase isoforms and their therapeutic potentials 142
Sonde diagnostiche per evidenziare all’infrarosso cellule e tessuti affetti da condizioni patologiche o metaboliche 142
Lactate dehydrogenase-A inhibition induces human glioblastoma multiforme stem cell differentiation and death 141
Systems Structural Biology Analysis of Ligand Effects on ERα Predicts Cellular Response to Environmental Estrogens and Anti-hormone Therapies 141
Phosphonomethylphosphorylmethyl(oxy)-analogues of geranylgeranyl diphosphate as stable and selective geranylgeranyl protein transferase inhibitors 140
A Polymer-Supported Phosphazine as a Stable and Practical Reagent in the Three-Component Synthesis of Substituted (Cyclopentadienyl)tricarbonylrhenium Complexes 139
Characterization of the Saffron Derivative Crocetin as an Inhibitor of Human Lactate Dehydrogenase 5 in the Antiglycolytic Approach against Cancer 139
Discovery of N-Hydroxyindole-Based Inhibitors of Human Lactate Dehydrogenase Isoform a (LDH-A) as Starvation Agents against Cancer Cells 138
Dual Targeting of the Warburg Effect with a Glucose-Conjugated Lactate Dehydrogenase Inhibitor 138
METAL SALT-PROMOTED ALDOL REACTION OF SILYL ENOL ETHERS WITH ALDEHYDES 137
Estrogen receptor ligands: a patent review update 137
7-Nitrobenzofurazan (NBD)-Derivatives Of 5'-N-Ethylcarboxamidoadenosine (NECA) As New Fluorescent Probes For Human A3 Adenosine Receptors 136
COMPOUNDS INHIBITING THE ENZYME LACTATE DEHYDROGENASE (LDH), PHARMACEUTICAL COMPOSITIONS AND USES THEREOF 136
An update on therapeutic opportunities offered by cancer glycolytic metabolism 134
Glucose transporters: production, crystallization and inhibition 134
NO-Sartans: A New Class of Pharmacodynamic Hybrids as Cardiovascular Drugs 133
Pharmacological study on the cardiovascular activity of no-sartans, pharmacodynamic hybridsexhibiting at1-antagonist and no-donor properties 132
CB2-Selective Cannabinoid Receptor Ligands: Synthesis, Pharmacological Evaluation, and Molecular Modeling Investigation of 1,8-Naphthyridin-2(1H)-one-3-carboxamides 132
Selective activators of estrogen receptor beta based on the aldoxime and ketoxime scaffolds 130
Synthesis of sulfonamide-containing N-hydroxyindole-2-carboxylates as inhibitors of human lactate dehydrogenase-isoform 5 130
Reactive Oxygen Species Synergize to Potently and Selectively Induce Cancer Cell Death 130
Assessing the differential action on cancer cells of LDH-A inhibitors based on the N-hydroxyindole-2-carboxylate (NHI) and malonic (Mal) scaffolds 128
Antiproliferative oxime derivatives that inhibit glucose transporter 1 (GLUT1) in cancer cells 128
A Virtual Screening Study for Lactate Dehydrogenase 5 Inhibitors by using a Pharmacophore-Based Approach 128
Preclinical emergence of novel lactate dehydrogenase inhibitors as potent antitumor agents in hypoxic models of pancreatic cancer: molecular mechanisms underlying their synergistic interaction with gemcitabine 127
Synthesis of stable analogues of geranylgeranyl diphosphate possessing a (Z,E,E)-geranylgeranyl side chain, docking analysis, and biological assays for prenyl protein transferase inhibition 126
Identification of new FYN kinase inhibitors using a FLAP-based approach 126
Tackling tumors by exploiting their glucose avidity and high rate of glycolysis 126
Design, Synthesis, and Evaluation of GLUT Inhibitors 126
Hypoxia-activated lysyl oxidase (LOX) inhibitors in the treatment of highly invasive and metastatic cancer 125
Ceramide analogues in apoptosis: a new strategy for anticancer drug development 124
New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2) 124
Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia 124
New Benzopyran-Based Openers of the Mitochondrial ATP-Sensitive Potassium Channel with Potent Anti-Ischemic Properties 123
Small-molecule inhibitors of human LDH5 122
Boronic Acids in the Three-Component Synthesis of Carbon-Substituted Cyclopentadienyl Tricarbonyl Rhenium Complexes 121
Metabolically labile cannabinoid esters: A ‘soft drug’ approach for the development of cannabinoid-based therapeutic drugs 121
Anticancer agents interacting with membrane glucose transporters 121
Salicylketoximes that target glucose transporter 1 restrict energy supply to lung cancer cells 121
Bioreductively Activated Lysyl Oxidase Inhibitors against Hypoxic Tumours 120
Cyclic Ketoximes as Estrogen Receptorβ Selective Agonists 120
Sulfonamido-derivatives of unsubstituted carbazoles as BACE1 inhibitors 120
Binding investigation and preliminary optimisation of the 3-amino-1,2,4-triazin-5(2H)-one core for the development of new Fyn inhibitors 120
Spirocyclic Benzopyran-based derivatives as new anti-ischemic activators of mitochondrial ATP-sensitive potassium channel 120
Oxime-based inhibitors of glucose transporter 1 displaying antiproliferative effects in cancer cells 119
Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53-independent pathways 119
New N-n-propyl-substituted 3-Aryl and 3-Cyclohexyl piperidines as partial agonists at the D4 dopamine receptor 118
A specific inhibitor of lactate dehydrogenase overcame the resistance toward gemcitabine in hypoxic mesothelioma cells, and modulated the expression of the human equilibrative transporter-1 118
a) Analgesici "pesanti": i Dramadoli; b) Ombrelli molecolari 117
Heterogeneous Asymmetric Epoxidation of Unfunctionalized Olefins Catalyzed by Polymer-Bound (Salen)manganese Complexes 117
Diaryl-substituted salicyl- and anthranyl-ketoximes as potential estrogen receptor ligands 117
Synthesis of a Resveratrol Analogue with High Ceramide-Mediated Proapoptotic Activity on Human Breast Cancer Cells 117
N-Hydroxyindole-based inhibitors of lactate dehydrogenase against cancer cell proliferation 117
a) Dendrimeri a rilascio controllato di ossido d'azoto; b) Platensimicina: un nuovo antibiotico per un nuovo target 116
Radiosensitizing potentialof small organic molecules toward hypoxic tumor cells in the radiotherapy 116
Drug-likeness of multiple-binding drugs 115
Discovery of long-chain salicylketoxime derivatives as monoacylglycerol lipase (MAGL) inhibitors 115
Curaxins: A New Family of Non-genotoxic Multitargeted Anticancer Agents 114
a) Arricchimento isotopico con B-10 per migliorare le radioterapie antitumorali di tipo BNCT; b) Antagonisti istaminici anti-H3 a struttura chinazolinica; c) Cannabinoidi non psicotropi ad azione analgesica periferica; d) Blocco selettivo di un canale del sodio: nuova speranza per il dolore neuropatico e infiammatorio? 113
Evaluation of the NO-releasing properties of NO-donor linkers 113
BACE1 inhibitory activities of enantiomerically pure, variously substituted N-(3-(4-benzhydrylpiperazin-1-yl)-2-hydroxypropyl) arylsulfonamides 113
Selective and potent agonists for estrogen receptor beta derived from molecular refinements of salicylaldoximes 113
Variously substituted (phosphonoacetamido)oxy analogues of geranylgeranyl diphosphate (GGdP) as GGdP-transferase (GGTase) inhibitors and antiproliferative agents 113
Computationally driven discovery of phenyl(piperazin-1-yl)methanone derivatives as reversible monoacylglycerol lipase (MAGL) inhibitors 113
New activators of SIRT1 enzyme for the treatment of cardiovascular and cardiometabolic pathologies 113
a) Antimalarici ad azione inibitoria sulla farnesilazione proteica nel plasmodio. b) Un "dolce" trattamento anti-rughe per la pelle 112
Biphenyl-Derivatives Possessing Tertiary Amino Groups as ß-Secretase (BACE1) Inhibitors 112
Antiproliferative activity and cell cycle analysis of 2-(3,5-dihydroxyphenyl)-6-hydroxybenzothiazole on MCF-7 breast and HCT-15 colon cancer cell lines. 112
Natural compounds as inhibitors of lactate dehydrogenase 112
Diagnostic probes to detect cells and tissues afflicted with a pathological or metabolic condition by means of infrared spectroscopy 112
Synthesis and antiviral properties of novel analogues of monophosphate and diphosphate bioactive forms of acyclovir 111
Development of terphenyl-2-methyloxazol-5(4H)-one derivatives as selective reversible MAGL inhibitors 111
Synthesis of aniline-type analogues of farnesyl diphosphate and their biological assays for prenyl protein transferase inhibitory activity 111
Triazole-substituted N-hydroxyindol-2-carboxylates as inhibitors of isoform 5 of human lactate dehydrogenase (hLDH5) 110
Crystallographic Evidence for the Electronic Distribution in (2,4-Cyclopentadien-1-ylidenehydrazono)triphenylphosphorane 109
QSAR models for predicting enzymatic hydrolysis of new chemical entities in 'soft-drug' design 109
Totale 13.343
Salva come PNG Salva come JPEG
Categoria #
all - tutte 71.086
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 71.086
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.597 0 0 0 0 352 436 455 273 349 241 365 126
2020/20212.282 195 119 124 131 237 157 163 236 260 143 151 366
2021/20223.401 116 293 80 199 521 490 129 194 84 120 180 995
2022/20233.837 489 497 260 395 467 506 41 296 606 29 205 46
2023/20243.386 446 423 353 261 489 585 127 102 57 75 123 345
2024/20251.346 84 393 254 528 87 0 0 0 0 0 0 0
Totale 27.649